Conclusion:

Raymond Sinatra, MD: Okay, well I want to thank everyone on the panel for just the excellent, excellent statements and answers to questions, I've learned a lot. I think we can conclude that while we're all concerned about the diversion and death associated with abuse of opioids, particularly the sustained release opioids, we do not want to see quotas for OxyContin or any of these other products. We all know that these restrictions will not only prevent diversion but are going to harm many of our patients, millions of our patients who suffer from severe chronic pain. And as Commander Burke said, we must not allow those who divert these drugs to negatively impact the legitimate right of the many who gain comfort from these products. So I want to thank you all again for your time and I look forward to meeting with you again and discuss this in the future.